{
  "insp_id": "57151544450559",
  "layout": "a",
  "customer_id": "352",
  "customer_name": "Millennium Bioresearch Inc",
  "customer_addr": "1765 Wentz Road\nP.O. Box 178\nSpinnerstown, PA 18967",
  "certificate": "23-R-0061",
  "site_id": "001",
  "site_name": "MB RESEARCH LABS, INC.",
  "insp_type": "ROUTINE INSPECTION",
  "date": "26-FEB-2015",
  "report_date": "26-FEB-2015",
  "citations": [
    {
      "code": "2.31(e)(4)",
      "kind": "",
      "repeat": false,
      "desc": "INSTITUTIONAL ANIMAL CARE AND USE COMMITTEE (IACUC).",
      "narrative": "Section 2.31(e)(4) IACUC: Section 14.5 in the new proposal format no longer specifies the facility SOP describing\nhow pain will be addressed, if pain does occur as a result of the nature of the test article being used. Section 6.3.1\nin proposal 2200-06 for anesthetic and/or analgesic treatment is not clearly written for the continued administration\nof buprenorphine. The terms \"at the discretion of the Study Director\" and \"may be administered\" are not adequate.\nPain must be relieved unless withholding relief is justified for scientific reasons in writing in the proposal. A proposal\nto conduct an activity involving animals must include a description of procedures designed to assure that discomfort\nand pain to animals will be limited to that which is unavoidable for the conduct of scientifically valuable research,\nincluding provisions for the use of analgesic, anesthetic, and tranquillizing drugs where indicated and appropriate to\nminimize discomfort and pain to animals. Proposal 2200-06 must clearly describe the administration of\nbuprenorphine to the rabbits. All proposals must include or specifically reference how pain to animals will be\naddressed. Correct by March 26, 2015.\nAn exit briefing was conducted with the facility institutional official."
    }
  ],
  "narrative": "2.31(e)(4)\nINSTITUTIONAL ANIMAL CARE AND USE COMMITTEE (IACUC).\nSection 2.31(e)(4) IACUC: Section 14.5 in the new proposal format no longer specifies the facility SOP describing\nhow pain will be addressed, if pain does occur as a result of the nature of the test article being used.  Section 6.3.1\nin proposal 2200-06 for anesthetic and/or analgesic treatment is not clearly written for the continued administration\nof buprenorphine.  The terms \"at the discretion of the Study Director\" and \"may be administered\" are not adequate. \nPain must be relieved unless withholding relief is justified for scientific reasons in writing in the proposal.  A proposal\nto conduct an activity involving animals must include a description of procedures designed to assure that discomfort\nand pain to animals will be limited to that which is unavoidable for the conduct of scientifically valuable research,\nincluding provisions for the use of analgesic, anesthetic, and tranquillizing drugs where indicated and appropriate to\nminimize discomfort and pain to animals.  Proposal 2200-06 must clearly describe the administration of\nbuprenorphine to the rabbits.  All proposals must include or specifically reference how pain to animals will be\naddressed.  Correct by March 26, 2015.\nAn exit briefing was conducted with the facility institutional official.",
  "animals_total": 42,
  "species": [
    {
      "count": 42,
      "scientific": "Oryctolagus cuniculus",
      "common": "EUROPEAN RABBIT"
    }
  ]
}